Koen Augustyns

List of Publications by Year
in descending order

194 papers	6,417 citations	57758 44 h-index	98798 67 g-index
210 all docs	210 docs citations	210 times ranked	7560 citing authors

#	Article	IF	Citations
1	Kinetic Investigation of Chemokine Truncation by CD26/Dipeptidyl Peptidase IV Reveals a Striking Selectivity within the Chemokine Family. Journal of Biological Chemistry, 2001, 276, 29839-29845.	3.4	249
2	Extended Structureâ€“Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP). Journal of Medicinal Chemistry, 2014, 57, 3053-3074.	6.4	169
3	Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. ACS Medicinal Chemistry Letters, 2013, 4, 491-496.	2.8	153
4	When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157. Cell Death and Differentiation, 2017, 24, 1100-1110.	11.2	149
5	Truncation of Macrophage-derived Chemokine by CD26/ Dipeptidyl-Peptidase IV beyond Its Predicted Cleavage Site Affects Chemotactic Activity and CC Chemokine Receptor 4 Interaction. Journal of Biological Chemistry, 1999, 274, 3988-3993.	3.4	142
6	Fluoro-Olefins as Peptidomimetic Inhibitors of Dipeptidyl Peptidases. Journal of Medicinal Chemistry, 2005, 48, 1768-1780.	6.4	136
7	In Vitro Antioxidant Profile of Phenolic Acid Derivatives. Free Radical Research, 2002, 36, 711-716.	3.3	134
8	Regulation of intestinal permeability: The role of proteases. World Journal of Gastroenterology, 2017, 23, 2106.	3.3	124
9	Synthesis and evaluation of caffeic acid amides as antioxidants. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 215-217.	2.2	121
10	The Unique Properties of Dipeptidyl-peptidase IV (DPP IV I CD26) and the Therapeutic Potential of DPP IV Inhibitors. Current Medicinal Chemistry, 1999, 6, 311-327.	2.4	119
11	Inhibitors Targeting RIPK1/RIPK3: Old and New Drugs. Trends in Pharmacological Sciences, 2020, 41, 209-224.	8.7	106
12	Inhibitors of the Purine Salvage Pathway: A Valuable Approach for Antiprotozoal Chemotherapy?. Current Medicinal Chemistry, 2010, 17, 2456-2481.	2.4	94
13	Molecular, functional and structural properties of the prolyl oligopeptidase of Trypanosoma cruzi (POP Tc80), which is required for parasite entry into mammalian cells. Biochemical Journal, 2005, 388, 29-38.	3.7	89
14	Novel Ferroptosis Inhibitors with Improved Potency and ADME Properties. Journal of Medicinal Chemistry, 2016, 59, 2041-2053.	6.4	88
15	Structureâ^'Activity Relationship of Diaryl Phosphonate Esters as Potent Irreversible Dipeptidyl Peptidase IV Inhibitors. Journal of Medicinal Chemistry, 1999, 42, 1041-1052.	6.4	83
16	The Therapeutic Potential of Inhibitors of Dipeptidyl Peptidase IV (DPP IV) and Related Proline-Specific Dipeptidyl Aminopeptidases. Current Medicinal Chemistry, 2005, 12, 971-998.	2.4	81
17	Discovery of Novel, Drug-Like Ferroptosis Inhibitors with in Vivo Efficacy. Journal of Medicinal Chemistry, 2018, 61, 10126-10140.	6.4	80
18	Trypanothione as a Target in the Design of Antitrypanosomal and Antileishmanial Agents. Current Pharmaceutical Design, 2001, 7, 1117-1141.	1.9	76

#	Article	IF	Citations
19	Prolyl oligopeptidase stimulates the aggregation of Î±-synuclein. Peptides, 2008, 29, 1472-1478.	2.4	76
20	ClpP Protease, a Promising Antimicrobial Target. International Journal of Molecular Sciences, 2019, 20, 2232.	4.1	75
21	Natural Substrates of Dipeptidyl Peptidase IV. Advances in Experimental Medicine and Biology, 2002, 477, 67-87.	1.6	71
22	Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. Basic Research in Cardiology, 2013, 108, 350.	5.9	71
23	Synthesis and Antiplasmodial Activity of Aminoalkylamino-Substituted Neocryptolepine Derivatives. Journal of Medicinal Chemistry, 2009, 52, 2979-2988.	6.4	69
24	Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. Cell Death and Disease, 2017, 8, e2904-e2904.	6.3	69
25	Incorporation of hexose nucleoside analogues into oligonucleotides: synthesis, base-pairing properties and enzymatic stability. Nucleic Acids Research, 1992, 20, 4711-4716.	14.5	68
26	Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). Biochemical Journal, 2005, 386, 315-324.	3.7	67
27	Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biological Chemistry, 2011, 392, 189-98.	2.5	66
28	Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: Isoindoline containing inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4159-4162.	2.2	65
29	Dipeptidyl peptidase 8/9-like activity in human leukocytes. Journal of Leukocyte Biology, 2007, 81, 1252-1257.	3.3	63
30	ATG4B inhibitors with a benzotropolone core structure block autophagy and augment efficiency of chemotherapy in mice. Biochemical Pharmacology, 2017, 138, 150-162.	4.4	61
31	Development of Irreversible Diphenyl Phosphonate Inhibitors for Urokinase Plasminogen Activator. Journal of Medicinal Chemistry, 2004, 47, 2411-2413.	6.4	60
32	Adhesion of PLGA or EudragitÂ®/PLGA nanoparticles to Staphylococcus and Pseudomonas. International Journal of Pharmaceutics, 2008, 349, 234-240.	5.2	60
33	Targeting ferroptosis protects against experimental (multi)organ dysfunction and death. Nature Communications, 2022, 13, 1046.	12.8	60
34	Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes. Expert Opinion on Therapeutic Patents, 2003, 13, 499-510.	5.0	59
35	Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogs: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides. Journal of Medicinal Chemistry, 1990, 33, 1833-1839.	6.4	54
36	A New Approach Towards the Synthesis of 3-Amino-6-(hetero)arylpyridazines Based on Palladium Catalyzed Cross-coupling Reactions. Tetrahedron, 2000, 56, 1777-1781.	1.9	54

#	Article	IF	Citations
37	Acyclic oligonucleotides: possibilities and limitations. Tetrahedron, 1993, 49, 7223-7238.	1.9	52
38	Small, Potent, and Selective Diaryl Phosphonate Inhibitors for Urokinase-Type Plasminogen Activator with In Vivo Antimetastatic Properties. Journal of Medicinal Chemistry, 2007, 50, 6638-6646.	6.4	52
39	Irreversible Inhibition of Dipeptidyl Peptidase 8 by Dipeptide-Derived Diaryl Phosphonates. Journal of Medicinal Chemistry, 2007, 50, 5568-5570.	6.4	51
40	Structureâ€“Activity Relationship Studies on Isoindoline Inhibitors of Dipeptidyl Peptidases 8 and 9 (DPP8, DPP9): Is DPP8-Selectivity an Attainable Goal?. Journal of Medicinal Chemistry, 2011, 54, 5737-5746.	6.4	51
41	Prolyl Peptidases Related to Dipeptidyl Peptidase IV: Potential of Specific Inhibitors in Drug Discovery.. Current Topics in Medicinal Chemistry, 2007, 7, 621-635.	2.1	50
42	Influence of the incorporation of (S)-9-(3,4-dihydroxybutyl) adenine on the enzymatic stability and base-pairing properties of oligodeoxynucleotides. Nucleic Acids Research, 1991, 19, 2587-2593.	14.5	49
43	Prolyl oligopeptidase of Trypanosoma brucei hydrolyzes native collagen, peptide hormones and is active in the plasma of infected mice. Microbes and Infection, 2010, 12, 457-466.	1.9	49
44	Prolylisoxazoles: potent inhibitors of prolyloligopeptidase with antitrypanosomal activity. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2875-2878.	2.2	48
45	DPP8/DPP9 inhibition elicits canonical Nlrp1b inflammasome hallmarks in murine macrophages. Life Science Alliance, 2019, 2, e201900313.	2.8	47
46	Rapid Parallel Synthesis of Dipeptide Diphenyl Phosphonate Esters as Inhibitors of Dipeptidyl Peptidases. ACS Combinatorial Science, 2003, 5, 336-344.	3.3	44
47	Enzyme Activity and Immunohistochemical Localization of Dipeptidyl Peptidase 8 and 9 in Male Reproductive Tissues. Journal of Histochemistry and Cytochemistry, 2009, 57, 531-541.	2.5	44
48	Structural determinants for ligand binding and catalysis of â€¨triosephosphate isomerase. FEBS Journal, 2001, 268, 5189-5196.	0.2	42
49	Synthesis of 2,4-dideoxy-.beta.-D-erythro-hexopyranosyl nucleosides. Journal of Organic Chemistry, 1993, 58, 2977-2982.	3.2	41
50	Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: The pivotal role of vasoactive intestinal peptide. Peptides, 2010, 31, 585-591.	2.4	41
51	Searching for New Leads for Tuberculosis: Design, Synthesis, and Biological Evaluation of Novel 2-Quinolin-4-yloxyacetamides. Journal of Medicinal Chemistry, 2016, 59, 6709-6728.	6.4	41
52	Î³-Amino-Substituted Analogues of 1-[(S)-2,4-Diaminobutanoyl]piperidine as Highly Potent and Selective Dipeptidyl Peptidase II Inhibitors. Journal of Medicinal Chemistry, 2004, 47, 2906-2916.	6.4	40
53	Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes. Expert Opinion on Therapeutic Patents, 2005, 15, 1387-1407.	5.0	40
54	Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3412-3417.	2.2	39

#	Article	IF	Citations
55	Design, Synthesis, and SAR of Potent and Selective Dipeptide-Derived Inhibitors for Dipeptidyl Peptidases. Journal of Medicinal Chemistry, 2003, 46, 5005-5014.	6.4	38
56	Development of a novel antibodyâ€“tetrazine conjugate for bioorthogonal pretargeting. Organic and Biomolecular Chemistry, 2016, 14, 7544-7551.	2.8	38
57	Development of potent and selective dipeptidyl peptidase II inhibitors. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2825-2828.	2.2	37
58	Functional Role of the Conserved Active Site Proline of Triosephosphate Isomeraseâ€‚â€¡. Biochemistry, 2006, 45, 15483-15494.	2.5	37
59	Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases. World Journal of Gastroenterology, 2016, 22, 10275.	3.3	37
60	Search for substrates for prolyl oligopeptidase in porcine brain. Peptides, 2005, 26, 2536-2546.	2.4	36
61	RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680). Cell Death and Disease, 2018, 9, 211.	6.3	36
62	Evaluation of Nucleoside Hydrolase Inhibitors for Treatment of African Trypanosomiasis. Antimicrobial Agents and Chemotherapy, 2010, 54, 1900-1908.	3.2	35
63	Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV. European Journal of Medicinal Chemistry, 1997, 32, 301-309.	5.5	34
64	Diphenyl Phosphonate Inhibitors for the Urokinase-Type Plasminogen Activator:â€‰ Optimization of the P4 Position. Journal of Medicinal Chemistry, 2006, 49, 5785-5793.	6.4	34
65	Intragraft DPP IV Inhibition Attenuates Post-transplant Pulmonary Ischemia/Reperfusion Injury After Extended Ischemia. Journal of Heart and Lung Transplantation, 2007, 26, 174-180.	0.6	33
66	N-Arylmethyl substituted iminoribitol derivatives as inhibitors of a purine specific nucleoside hydrolase. Bioorganic and Medicinal Chemistry, 2008, 16, 6752-6763.	3.0	33
67	Newly developed serine protease inhibitors decrease visceral hypersensitivity in a postâ€inflammatory rat model for irritable bowel syndrome. British Journal of Pharmacology, 2018, 175, 3516-3533.	5.4	33
68	Tozasertib Analogues as Inhibitors of Necroptotic Cell Death. Journal of Medicinal Chemistry, 2018, 61, 1895-1920.	6.4	32
69	Dipeptide-derived diphenyl phosphonate esters: mechanism-based inhibitors of dipeptidyl peptidase IV. Biochimica Et Biophysica Acta - General Subjects, 1996, 1290, 76-82.	2.4	31
70	Synthesis of (E)- and (Z)-fluoro-olefin analogues of potent dipeptidyl peptidase IV inhibitors. Tetrahedron Letters, 2003, 44, 6231-6234.	1.4	31
71	In vivo evaluation of 18F-labeled TCO for pre-targeted PET imaging in the brain. Nuclear Medicine and Biology, 2014, 41, 513-523.	0.6	31
72	Identification and Profiling of Hydantoinsâ€”A Novel Class of Potent Antimycobacterial DprE1 Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 11221-11249.	6.4	30

#	Article	IF	Citations
73	Dipeptidyl Î±-fluorovinyl Michael acceptors: Synthesis and activity against cysteine proteases. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6563-6566.	2.2	29
74	Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold. Journal of Medicinal Chemistry, 2015, 58, 9238-9257.	6.4	29
75	Substrate-assisted Leaving Group Activation in Enzyme-catalyzed N-Glycosidic Bond Cleavage. Journal of Biological Chemistry, 2005, 280, 14799-14802.	3.4	28
76	Synthesis of 6-methyl-6H-indolo[3,2-c]isoquinoline and 6-methyl-6H-indolo[2,3-c]isoquinoline: two new unnatural isoquinoline isomers of the cryptolepine series. Tetrahedron, 2008, 64, 11802-11809.	1.9	28
77	Î±â€Ketoheterocycles as Inhibitors of Leishmania mexicana Cysteine Protease CPB. ChemMedChem, 2010, 5, 1734-1748.	3.2	28
78	Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma. Pancreatology, 2016, 16, 829-838.	1.1	28
79	The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors. Current Medicinal Chemistry, 1999, 6, 311-27.	2.4	28
80	Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: Identification of dipeptide derived leads. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4154-4158.	2.2	27
81	In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma. Biochemical Pharmacology, 2009, 77, 228-237.	4.4	27
82	Influence of the Incorporation of 1â€(2,3â€Dideoxyâ€Î²â€Dâ€Erythroâ€Hexopyranosyl)â€Thymine on the Enzymatic Stability and Baseâ€Pairing Properties of Oligodeoxynucleotides. Bulletin Des SociÃ©tÃ©s Chimiques Belges, 1992, 101, 119-130.	0.0	27
83	Î²-Fluorinated proline derivatives: potential transition state inhibitors for proline selective serine dipeptidases. Tetrahedron Letters, 2003, 44, 969-972.	1.4	25
84	Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP). ACS Medicinal Chemistry Letters, 2019, 10, 1173-1179.	2.8	25
85	Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 1: Substitution of the glycine carboxylic acid group. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2553-2556.	2.2	24
86	Design and evaluation of Trypanosoma brucei metacaspase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2001-2006.	2.2	24
87	P2-Substituted N-Acylprolylpyrrolidine Inhibitors of Prolyl Oligopeptidase: Biochemical Evaluation, Binding Mode Determination, and Assessment in a Cellular Model of Synucleinopathy. Journal of Medicinal Chemistry, 2012, 55, 9856-9867.	6.4	24
88	Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398. International Journal of Pharmaceutics, 2014, 475, 238-244.	5.2	24
89	Schistosomicidal and molluscicidal activities of aminoalkylamino substituted neo- and norneocryptolepine derivatives. Pharmaceutical Biology, 2012, 50, 134-140.	2.9	23
90	Synthesis and Evaluation of a Zr-89-Labeled Monoclonal Antibody for Immuno-PET Imaging of Amyloid-Î² Deposition in the Brain. Molecular Imaging and Biology, 2016, 18, 598-605.	2.6	23

#	Article	IF	Citations
91	Novel drug discovery strategies for atherosclerosis that target necrosis and necroptosis. Expert Opinion on Drug Discovery, 2018, 13, 477-488.	5.0	23
92	Î±-Amino Diphenyl Phosphonates as Novel Inhibitors of Escherichia coli ClpP Protease. Journal of Medicinal Chemistry, 2019, 62, 774-797.	6.4	23
93	The role of the S1 binding site of carboxypeptidase M in substrate specificity and turn-over. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2007, 1774, 267-277.	2.3	22
94	Synthesis and biochemical evaluation of guanidino-alkyl-ribitol derivatives as nucleoside hydrolase inhibitors. European Journal of Medicinal Chemistry, 2008, 43, 315-326.	5.5	22
95	Purification and characterization of dipeptidyl peptidase IV-like enzymes from bovine testes. Frontiers in Bioscience - Landmark, 2008, Volume, 3558.	3.0	22
96	Crystal structures of T. vivax nucleoside hydrolase in complex with new potent and specific inhibitors. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2009, 1794, 953-960.	2.3	22
97	A Convenient One-Pot Preparation of Disubstituted Phosphinic Acids Derived from Simple Amino Acids and Proline. Synthesis, 1995, 1995, 1074-1076.	2.3	21
98	CD26/Dipeptidylpeptidase IVâ€“targeted Therapy of Acute Lung Rejection in Rats. Journal of Heart and Lung Transplantation, 2006, 25, 1109-1116.	0.6	21
99	Dipeptidyl peptidase II and leukocyte cell death. Biochemical Pharmacology, 2006, 72, 70-79.	4.4	21
100	Investigation on the stability of the Dde protecting group used in peptide synthesis: migration to an unprotected lysine¹. Chemical Biology and Drug Design, 1998, 51, 127-133.	1.1	21
101	Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma. Analytical Biochemistry, 2010, 396, 152-154.	2.4	21
102	Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1. Antiviral Research, 2014, 101, 113-121.	4.1	20
103	The power metric: a new statistically robust enrichment-type metric for virtual screening applications with early recovery capability. Journal of Cheminformatics, 2017, 9, 7.	6.1	20
104	Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 2: Substitution of the glycine part. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2703-2705.	2.2	19
105	1,2,3-Triazolylalkylribitol derivatives as nucleoside hydrolase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2523-2526.	2.2	19
106	Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA). Bioorganic and Medicinal Chemistry, 2012, 20, 1557-1568.	3.0	19
107	Inhibitor screening and enzymatic activity determination for autophagy target Atg4B using a gel electrophoresis-based assay. European Journal of Medicinal Chemistry, 2016, 123, 631-638.	5.5	19
108	Synthesis of 1-(2,4-dideoxy-Î²-D-erythro-hexopyranosyl)thymine and its incorporation into oligonucleotides. Bioorganic and Medicinal Chemistry Letters, 1992, 2, 945-948.	2.2	18

#	Article	IF	Citations
109	Primary Graft Dysfunction in Lung Transplantation: The Role of CD26/Dipeptidylpeptidase IV and Vasoactive Intestinal Peptide. Transplantation, 2009, 87, 1140-1146.	1.0	18
110	Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-Î²-<scp>d</scp>-Ribose Oxidase (DprE1) Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 5367-5386.	6.4	18
111	Hybridization specificity, enzymatic activity and biological (Ha-ras) activity of oligonucleotides containing 2,4-dideoxy-Î²-D-erythro-hexopyranosyl nucleosides. Nucleic Acids Research, 1993, 21, 4670-4676.	14.5	17
112	A new synthetic method for proline diphenyl phosphonates. Tetrahedron Letters, 1995, 36, 3755-3758.	1.4	17
113	Ischemia/Reperfusion Injury: The Role of CD26/Dipeptidyl-Peptidase-IV-Inhibition in Lung Transplantation. Transplantation Proceedings, 2006, 38, 3369-3371.	0.6	17
114	Reverse Transcriptase Inhibitors as Microbicides. Current HIV Research, 2012, 10, 27-35.	0.5	17
115	Caspase-3 probes for PET imaging of apoptotic tumor response to anticancer therapy. Organic and Biomolecular Chemistry, 2019, 17, 4801-4824.	2.8	17
116	Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission. Journal of Antimicrobial Chemotherapy, 2013, 68, 2038-2047.	3.0	16
117	Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold. MedChemComm, 2014, 5, 1700-1707.	3.4	16
118	Synthesis and in vivo preclinical evaluation of an 18F labeled uPA inhibitor as a potential PET imaging agent. Nuclear Medicine and Biology, 2014, 41, 477-487.	0.6	16
119	Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling. European Journal of Medicinal Chemistry, 2017, 139, 482-491.	5.5	16
120	Improved stability of a novel fluorine-18 labeled TCO analogue for pretargeted PET imaging. Nuclear Medicine and Biology, 2019, 76-77, 36-42.	0.6	16
121	A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation. Scientific Reports, 2020, 10, 17268.	3.3	16
122	Novel triazine dimers with potent antitrypanosomal activity. European Journal of Medicinal Chemistry, 2018, 143, 306-319.	5.5	16
123	Synthesis of a new branched chain hexopyranosyl nucleoside: 1-[2â€²,3â€²-dideoxy-3â€²-C-(hydroxymethyl)-Î±-D-erythro-pentopyranosyl]-thymine. Tetrahedron, 1994, 50, 1189-1198.	1.9	15
124	Hexopyranosyl-Like Oligonucleotides. ACS Symposium Series, 1994, , 80-99.	0.5	15
125	Synthesis of Bicyclic Nâ€Arylmethylâ€Substituted Iminoribitol Derivatives as Selective Nucleoside Hydrolase Inhibitors. ChemMedChem, 2009, 4, 249-260.	3.2	15
126	Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assay. Analytical Biochemistry, 2010, 403, 114-116.	2.4	15

#	Article	IF	Citations
127	Structures of purine nucleosidase fromTrypanosoma bruceibound to isozyme-specific trypanocidals and a novel metalorganic inhibitor. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 1553-1566.	2.5	15
128	An Essential Signal Peptide Peptidase Identified in an RNAi Screen of Serine Peptidases of Trypanosoma brucei. PLoS ONE, 2015, 10, e0123241.	2.5	15
129	Development and Evaluation of Peptide-Based Prolyl Oligopeptidase Inhibitors - Introduction of N-Benzyloxycarbonyl-Prolyl-3-Fluoropyrrolidine as a Lead in Inhibitor Design. FEBS Journal, 1997, 250, 177-183.	0.2	14
130	Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs). Bioorganic and Medicinal Chemistry, 2011, 19, 5924-5934.	3.0	14
131	Vaginal Expression of Efflux Transporters and the Potential Impact on the Disposition of Microbicides in Vitro and in Rabbits. Molecular Pharmaceutics, 2014, 11, 4405-4414.	4.6	14
132	Structure-based protein engineering efforts with a monomeric TIM variant: the importance of a single point mutation for generating an active site with suitable binding properties. Protein Engineering, Design and Selection, 2008, 21, 257-266.	2.1	13
133	Synthesis, evaluation and structureâ€“activity relationships of triazine dimers as novel antiviral agents. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7174-7178.	2.2	13
134	Spectrophores as one-dimensional descriptors calculated from three-dimensional atomic properties: applications ranging from scaffold hopping to multi-target virtual screening. Journal of Cheminformatics, 2018, 10, 9.	6.1	13
135	Synthesis and preclinical evaluation of an 18 F labeled PDE7 inhibitor for PET neuroimaging. Nuclear Medicine and Biology, 2015, 42, 975-981.	0.6	12
136	Preclinical Evaluation of a Novel ¹⁸F-Labeled dTCO-Amide Derivative for Bioorthogonal Pretargeted Positron Emission Tomography Imaging. ACS Omega, 2020, 5, 4449-4456.	3.5	12
137	Synthesis of peptidyl acetals as inhibitors of prolyl endopeptidase. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1265-1270.	2.2	11
138	Polymer-assisted solution-phase parallel synthesis of dipeptide p-nitroanilides and dipeptide diphenyl phosphonates. Tetrahedron Letters, 2001, 42, 9135-9138.	1.4	11
139	The use of timeâ€averaged ³J_{HH} restrained molecular dynamics (tarâ€MD) simulations for the conformational analysis of fiveâ€membered ring systems: Methodology and applications. Journal of Computational Chemistry, 2010, 31, 561-572.	3.3	11
140	Asymmetric synthesis of Î³-chloro-Î±,Î²-diamino- and Î²,Î³-aziridino-Î±-aminoacylpyrrolidines and -piperidines via stereoselective Mannich-type additions of N-(diphenylmethylene)glycinamides across Î±-chloro-N-sulfinylimines. Beilstein Journal of Organic Chemistry, 2012, 8, 2124-2131.	2.2	11
141	Preclinical evaluation of [¹¹¹In]MICAâ€401, an activityâ€based probe for SPECT imaging of in vivo uPA activity. Contrast Media and Molecular Imaging, 2016, 11, 448-458.	0.8	11
142	Probing for improved selectivity with dipeptide-derived inhibitors of dipeptidyl peptidases 8 and 9: the impact of P1-variation. MedChemComm, 2016, 7, 433-438.	3.4	11
143	Efforts towards an Onâ€Target Version of the Groebkeâ€“Blackburnâ€“BienaymÃ© (GBB) Reaction for Discovery of Druglike Urokinase (uPA) Inhibitors. Chemistry - A European Journal, 2019, 25, 12380-12393.	3.3	11
144	The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma. Clinica Chimica Acta, 2019, 495, 154-160.	1.1	11

#	Article	IF	Citations
145	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds. Bioorganic and Medicinal Chemistry, 2014, 22, 5241-5248.	3.0	10
146	The first potent diphenyl phosphonate KLK4 inhibitors with unexpected binding kinetics. MedChemComm, 2015, 6, 1954-1958.	3.4	10
147	Selective Glucocorticoid Receptor Properties of GSK866 Analogs with Cysteine Reactive Warheads. Frontiers in Immunology, 2017, 8, 1324.	4.8	10
148	Screening of a PDE-focused library identifies imidazoles with in vitro and in vivo antischistosomal activity. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 9, 35-43.	3.4	10
149	Synthesis and evaluation of novel benzotropolones as Atg4B inhibiting autophagy blockers. Bioorganic Chemistry, 2019, 87, 163-168.	4.1	10
150	Local Colonic Administration of a Serine Protease Inhibitor Improves Post-Inflammatory Visceral Hypersensitivity in Rats. Pharmaceutics, 2021, 13, 811.	4.5	10
151	Sugar Modified Oligonucleotides. Nucleosides & Nucleotides, 1991, 10, 587-588.	0.5	9
152	Synthesis and evaluation of azaproline peptides as potential inhibitors of dipeptidyl peptidase IV and prolyl oligopeptidase. International Journal of Peptide Research and Therapeutics, 1995, 2, 198-202.	0.1	9
153	AN EFFICIENT SYNTHESIS OF ORTHOGONALLY PROTECTED SPERMIDINE. Synthetic Communications, 2002, 32, 319-328.	2.1	9
154	Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5032-5038.	2.2	9
155	The Effect of Organ-Specific CD26/DPP IV Enzymatic Activity Inhibitor-Preconditioning on Acute Pulmonary Allograft Rejection. Transplantation, 2009, 88, 478-485.	1.0	8
156	Evaluation of [¹⁸F]BR420 and [¹⁸F]BR351 as radiotracers for MMPâ€9 imaging in colorectal cancer. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 69-79.	1.0	8
157	Virtual screening for inhibitors of the human TSLP:TSLPR interaction. Scientific Reports, 2017, 7, 17211.	3.3	8
158	Evaluation of phthalazinone phosphodiesterase inhibitors with improved activity and selectivity against Trypanosoma cruzi. Journal of Antimicrobial Chemotherapy, 2020, 75, 958-967.	3.0	8
159	Lead Optimization of Phthalazinone Phosphodiesterase Inhibitors as Novel Antitrypanosomal Compounds. Journal of Medicinal Chemistry, 2020, 63, 3485-3507.	6.4	8
160	The effect of pharmacological inhibition of Serine Proteases on neuronal networks in vitro. PeerJ, 2019, 7, e6796.	2.0	8
161	VildagliptinâEDerived Dipeptidyl Peptidase 9 (DPP9) Inhibitors: Identification of a DPP8/9â€Specific Lead. ChemMedChem, 2022, 17, .	3.2	8
162	Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2,4-diaminobutanoyl)piperidines. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4777-4779.	2.2	7

#	Article	IF	Citations
163	Repositioning the Substrate Activity Screening (SAS) Approach as a Fragmentâ€Based Method for Identification of Weak Binders. ChemBioChem, 2014, 15, 2238-2247.	2.6	7
164	Synthesis of Î³,Î´â€Aziridino Î±â€Amino Acid Derivatives and their Stereoselective Ring Transformation to 2â€(Aminomethyl)â€1â€aminocyclopropanecarboxylic Acid Derivatives. European Journal of Organic Chemistry, 2014, 2014, 1220-1226.	2.4	7
165	Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity. European Journal of Medicinal Chemistry, 2017, 125, 890-901.	5.5	6
166	Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives. European Journal of Medicinal Chemistry, 2018, 151, 18-26.	5.5	6
167	In Vitro and In Situ Activity-Based Labeling of Fibroblast Activation Protein with UAMC1110-Derived Probes. Frontiers in Chemistry, 2021, 9, 640566.	3.6	6
168	Substrate Activity Screening (SAS) and Related Approaches in Medicinal Chemistry. ChemMedChem, 2016, 11, 467-476.	3.2	5
169	Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398. Journal of Antimicrobial Chemotherapy, 2016, 71, 1159-1168.	3.0	5
170	Decreased levels of active <scp>uPA</scp> and <scp>KLK</scp>8 assessed by [¹¹¹In]<scp>MICA</scp>â€401 binding correlate with the seizure burden in an animal model of temporal lobe epilepsy. Epilepsia, 2017, 58, 1615-1625.	5.1	5
171	Identification and Characterization of Approved Drugs and Drug-Like Compounds as Covalent Escherichia coli ClpP Inhibitors. International Journal of Molecular Sciences, 2019, 20, 2686.	4.1	5
172	Strecker-Derived Methodology for Library Synthesis of N-Acylated Î±-Aminonitriles. ACS Omega, 2021, 6, 1328-1338.	3.5	5
173	The Effect of a Novel Serine Protease Inhibitor on Inflammation and Intestinal Permeability in a Murine Colitis Transfer Model. Frontiers in Pharmacology, 2021, 12, 682065.	3.5	5
174	In Vivo Effects of a Potent, Selective Dppii Inhibitor. Advances in Experimental Medicine and Biology, 2006, 575, 73-85.	1.6	5
175	Abstract 5250: Optimization of an orthotopic mouse model for in vivo fluorescent uPA imaging in breast cancer. Cancer Research, 2012, 72, 5250-5250.	0.9	5
176	Exploration of the Active Site of Dipeptidyl Peptidase IV From Porphyromonas gingivalis. Advances in Experimental Medicine and Biology, 2004, 524, 29-35.	1.6	4
177	The Use of Supersaturation for the Vaginal Application of Microbicides: A Case Study with Dapivirine. Journal of Pharmaceutical Sciences, 2014, 103, 3696-3703.	3.3	4
178	Carboxylate isosteres for caspase inhibitors: the acylsulfonamide case revisited. Organic and Biomolecular Chemistry, 2017, 15, 7456-7473.	2.8	4
179	The Effect of Serine Protease Inhibitors on Visceral Pain in Different Rodent Models With an Intestinal Insult. Frontiers in Pharmacology, 2022, 13, .	3.5	4
180	Synthesis and electrophysiological characterization of cyclic morphiceptin analogues. Biochemical Pharmacology, 2004, 67, 1887-1895.	4.4	3

#	Article	IF	Citations
181	Lewis Acid Catalyzed Synthesis of N-Protected Diphenyl 1-AminoalkylÂphosphonates. Synthesis, 2005, 2005, 634-638.	2.3	3
182	In Vivo Amyloid-Î² Imaging in the APPPS1â€“21 Transgenic Mouse Model with a 89Zr-Labeled Monoclonal Antibody. Frontiers in Aging Neuroscience, 2016, 8, 67.	3.4	3
183	The use of small volume TOC analysis as complementary, indispensable tool in the evaluation of photocatalysts at lab-scale. Studies in Surface Science and Catalysis, 2010, 175, 321-324.	1.5	1
184	Development of Potent and Selective Dipeptidyl Peptidase II Inhibitors.. ChemInform, 2003, 34, no.	0.0	0
185	433: The Effect of Organ-Specific CD26/Dipeptidylpeptidase IV (DPP IV) â€“ Inhibitor â€“ Preconditioning on Acute Pulmonary Allograft Rejection in Rats. Journal of Heart and Lung Transplantation, 2008, 27, S216-S217.	0.6	0
186	439: Vasoactive Intestinal Peptide and CD26/Dipeptidyl-Peptidase IV: Influence on Ischemia/Reperfusion-Injury in a Mouse Model of Orthotopic Pulmonary Transplantation. Journal of Heart and Lung Transplantation, 2009, 28, S218.	0.6	0
187	Resistance Profile of the Diaryltriazine Non-nucleoside Reverse Transcriptase Inhibitor and Candidate Microbicide UAMC01398. AIDS Research and Human Retroviruses, 2014, 30, A212-A212.	1.1	0
188	Post-Inflammatory Visceral Hypersensitivity: An Important Role for Serine Proteases and in Particular Tryptase. Gastroenterology, 2017, 152, S211.	1.3	0
189	Selective Activity-Based Probes Targeting Fibroblast Activation Protein (FAP). Proceedings (mdpi), 2019, 22, 84.	0.2	0
190	The Role of CD26/DPP IV in Preservation of Early Pulmonary Graft Function. Advances in Experimental Medicine and Biology, 2006, 575, 231-235.	1.6	0
191	Abstract 3910: Targeting urokinase plasminogen activator: evaluation of activity-based imaging probes in an orthotopic breast cancer model.. , 2013, , .		0
192	Acyclic nucleosides: Useful for antisense constructs or as universal analogues for degenerate positions?. Collection of Czechoslovak Chemical Communications, 1993, 58, 98-101.	1.0	0
193	Molecular biochemical characterization of selective glucocorticoid receptor activities of GSK866 analogues with cysteine reactive warheads. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-5-6.	0.0	0
194	Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes. Expert Opinion on Therapeutic Patents, 2003, 13, 499-510.	5.0	0